Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Liz is Science Editor for Cancer Health, POZ, Hep and Real Health. She has been a health journalist and medical editor for more than 20 years, covering HIV, viral hepatitis, cancer and other health issues.
National survey finds HBV rate is four times higher than that of the overall U.S. population.
FDA warns that drinking Miracle Mineral Solution and similar products is potentially life-threatening.
The presence of less studied HCV genotypes may compromise cure rates.
Large European study finds that more than 1 in 10 people with HIV acquire HCV again.
Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.
National survey finds a majority of people with HBV or HCV don’t know their status.
Study finds people who took daily aspirin had a lower risk of NASH and advanced liver scarring.
CDC experts recommend the vaccine for children, teens and HIV-positive people.
Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.
Study in China sees an association with several cancer types, especially gastrointestinal malignancies.
Analysis of nearly 34,000 people finds no serious adverse events associated with direct-acting antiviral therapy.
Keytruda showed modest benefits for people with hepatocellular carcinoma, and combining Opdivo with Yervoy improved outcomes.
GS-4774 combined with Viread stimulates immune activity against the virus.
With the approval of Cyramza, there are now five targeted therapies for hepatocellular carcinoma.
Just over half of people who use drugs in eight cities are hepatitis C virus antibody positive.
Bulevirtide plus pegylated interferon shows promise for hard-to-treat coinfection.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.